

Platelet-Rich Plasma



Adrian D.K. Le, MD, Lawrence Enweze, MD, Malcolm R. DeBaun, MD,
Jason L. Dragoo, MD*

KEYWORDS

- Platelet-rich plasma • PRP • Orthobiologics • Regenerative medicine
- Tendinopathy • Osteoarthritis • Augmentation

KEY POINTS

- There is abundant high-quality level I evidence to recommend leukocyte-rich platelet-rich plasma (LR-PRP) injections for lateral epicondylitis and LP-PRP injections for osteoarthritis of the knee.
- There is a moderate amount of high-quality level I evidence to recommend LR-PRP injections for patellar tendinopathy and PRP injections for plantar fasciitis.
- There is currently insufficient high-quality evidence for recommendation, but small clinical trials have shown promising efficacy for PRP injections for rotator cuff tendinopathy, osteoarthritis of the hip, donor site pain in anterior cruciate ligament (ACL) reconstruction with patellar tendon autograft, and LP-PRP injections for high ankle sprains.
- The best available clinical evidence does not demonstrate efficacy of PRP injections for Achilles tendinopathy, acute fracture, or nonunion; surgical augmentation with PRP in rotator cuff repair, Achilles tendon repair, and ACL reconstruction; and efficacy has not been shown with PRP injections for muscle injuries, although preclinical studies suggest platelet-poor plasma may hold promise for muscle injuries, but clinical trials will be necessary to validate this.

INTRODUCTION

Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small volume of plasma produced by centrifuging a patient's own blood. Platelets contain a milieu of growth factors and mediators in their alpha granules (transforming growth factor [TGF]- β 1, platelet-derived growth factor, basic fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, insulinlike growth factor [IGF]-1),^{1,2} which are concentrated through the centrifugation process and then be delivered to an injury site to augment the body's natural healing process.³ The normal human platelet count ranges anywhere from 150,000 to 350,000/ μ L. Improvements in

Disclosure Statement: None (A.D.K. Le, L. Enweze, M.R. DeBaun). J.L. Dragoo – per the American Academy of Orthopaedic Surgeons Web site.

Department of Orthopedic Surgery, Stanford University, 450 Broadway Street, Redwood City, CA 94063, USA

* Corresponding author.

E-mail address: jdragoo@stanford.edu

Clin Sports Med 38 (2019) 17–44

<https://doi.org/10.1016/j.csm.2018.08.001>

0278-5919/19/© 2018 Elsevier Inc. All rights reserved.

sportsmed.theclinics.com

bone and soft tissue healing properties have been demonstrated with concentrated platelets of 1,000,000/ μL , and thus it is this concentration of platelets in a 5-mL volume of plasma that has been suggested as one working definition of PRP.^{2,4} Another proposed definition of PRP is any plasma fraction that concentrates platelets greater than baseline. A resultant threefold to fivefold increase in growth and differentiation factors can be expected with PRP compared with normal nonconcentrated whole blood. PRP preparations are typically further categorized into leukocyte-rich PRP (LR-PRP) preparations, defined as having a neutrophil concentration above baseline, and leukocyte-poor PRP (LP-PRP) preparations, defined as having a leukocyte (neutrophil) concentration below baseline.

PREPARATION AND COMPOSITION

Currently more than 16 commercial PRP systems are available on the market, and hence quite a bit of variation exists in the PRP collection and preparation protocol depending on the commercial system being used (Table 1), which gives each system's PRP unique properties.^{1,7-9} Each commercial system has a different platelet capture efficiency that results in different whole-blood volume requirements to achieve the necessary final platelet concentration for PRP. The commercial systems may also differ in their isolation method (1-step or 2-step centrifugation), the speed of centrifugation, and the type of collection tube system and operation. Generally, whole blood is usually collected and mixed with an anticoagulant factor, such as acid-citrate-dextrose, sodium citrate, or ethylene diamine tetra-acetic acid. Centrifugation then separates red blood cells (RBCs) from platelet-poor plasma (PPP) and the "buffy coat," which contains the concentrated platelets $\pm$ leukocytes. The platelet-concentrated layer is isolated using various processing techniques, and the RBC and PPP layers may be discarded. The platelets can then be directly injected into the patient or be "activated" via the addition of either calcium chloride or thrombin, which then causes the platelets to degranulate and release the growth and differentiation factors. Approximately 70% of the stored growth factors are released within the first 10 minutes of activation, and nearly 100% of the growth factors are released within 1 hour of activation.^{2,4} Small amounts of growth factors may continue to be produced by the platelet during the remainder of its life span (8–10 days).

The specific composition of PRP, however, likely varies not only from person to person but also when the isolation process is repeated in the same individual.⁹ Both patient-specific factors, including medications taken, and commercial system preparation methods are known to influence the specific makeup of PRP.⁸⁻¹⁰ The variability in the cellular composition of PRP preparations creates challenges in interpretation of the literature regarding the clinical efficacy of PRP.

Our current understanding appears to suggest that PRP with elevated leukocyte content, that is, leukocyte (neutrophil)-rich PRP (LR-PRP), is associated with proinflammatory effects.⁸ The elevated leukocyte (neutrophil) concentrations present in LR-PRP are also associated with elevated catabolic cytokines, such as interleukin (IL)-1 β , tumor necrosis factor (TNF)- α , and metalloproteinases,^{10,11} which may antagonize the anabolic cytokines contained within platelets. The clinical ramifications and cellular effects of these different PRP preparations, including leukocyte content, are still currently being elucidated. To better evaluate and summarize the best quality evidence available for various clinical indications for different PRP preparations, we have performed a systematic review of the literature, and present our methods and results in the following sections.

Table 1
Characteristics of PRP preparations from different commercially available systems

System	Company	Blood Volume Required, mL	Concentrated Volume Produced, mL	Processing Time, min	PPP Produced?	Increase in [Platelets], Times Baseline	Platelet Capture Efficiency, % Yield
Leukocyte-rich PRP							
Angel	Arthrex (Florida, USA)	52 ⁵	1–20 ^a	17 ⁵	+	10 ^a	56%–75% ⁵
GenesisCS	EmCyte (Florida, USA)	54 ⁵	6 ⁵	10 ⁵	+	4–7 ⁵	61% ± 12% ⁵
GPS III	Biomet (Now known as Zimmer Biomet, Indiana, USA)	54 ⁵	6 ⁵	15 ⁵	+	3–10 ⁵	70% ± 30% ⁵
Magellan	Isto Biologics/ Arteriocyte (Now known as Isto Biologics, Massachusetts, USA)	52 ⁵	3.5–7 ⁵	17 ⁵	+	3–15 ⁵	86% ± 41% ⁵
SmartPREP 2	Harvest (Now known as Terumo BCT, Colorado, USA)	54 ⁵	7 ⁵	14 ⁵	+	5–9 ⁵	94% ± 12% ⁵
Leukocyte-poor PRP							
Autologous Conditioned Plasma (ACP)	Arthrex	11 ⁶	4 ⁶	5 ⁶	–	1.3 ⁶	48% ± 7% ⁶
Cascade	MTF (New Jersey, USA)	18 ⁷	7.5 ⁷	6 ⁷	–	1.6 ⁷	68% ± 4% ⁷
Clear PRP	Harvest	54 ^a	6.5 ^a	18 ^a	+	3–6 ^a	62% ± 5% ^a
Pure PRP	EmCyte	50 ^a	6.5 ^a	8.5 ^a	+	4–7 ^a	76% ± 4% ^a

Abbreviations: PPP, platelet-poor plasma; PRP, platelet-rich plasma.

Plus minus sign signifies reported variance of platelet capture efficiency.

^a Data obtained from manufacturers' promotional literature or internal studies.

TREATMENT OF TENDON INJURIES

PRP has been most actively evaluated in the treatment of tendon injuries or tendinopathies (Table 2). Tendons and ligaments heal through a dynamic process, with stages of inflammation, cellular proliferation, and subsequent tissue remodeling. Many of the cytokines found in PRP are involved in the signaling pathways that occur during this restorative process.^{1,2} PRP may also promote neovascularization, which may not only increase the blood supply and nutrients needed for cells to regenerate the injured tissue, but may also bring new cells and remove debris from damaged tissue. Both these mechanisms of action are particularly attractive in chronic tendinopathy conditions in which the biologic milieu may be unfavorable for tissue healing. A recent systematic review and meta-analysis by Miller and colleagues⁴² concluded that injections of PRP were more efficacious than control injections for treatment of symptomatic tendinopathy.

Lateral Epicondylitis

Clinical studies have evaluated PRP in lateral epicondylitis for patients who have failed to respond to physical therapy. In the largest such study, Mishra and colleagues²⁰ evaluated 230 patients who failed to respond to at least 3 months of conservative treatment for lateral epicondylitis in a prospective cohort study. Patients were treated with LR-PRP and at 24 weeks, the patients who received LR-PRP reported a 71.5% improvement in their pain scores compared with a 56.1% improvement in the control group ($P = .019$). The percentage of patients reporting significant residual elbow tenderness at 24 weeks was 29.1% in the patient group receiving PRP compared with 54.0% in the control group ($P = .009$). There was a clinically meaningful and statistically significant improvement at 24 weeks in patients treated with LR-PRP versus active control injection of local anesthetic.

PRP may also provide longer continuous relief of symptoms for lateral epicondylitis than corticosteroid injection and therefore have a more sustainable treatment effect. Gosens and colleagues¹⁷ and Peerbooms and colleagues⁴³ evaluated the efficacy of LR-PRP versus corticosteroids in 100 patients who had a minimum 6-month history of recalcitrant chronic epicondylitis and had failed to respond to conservative management. Treatment success within this study was defined as, at minimum, a 25% reduction in the visual analog scale (VAS) score or Disability of Arm, Shoulder, and Hand score without a repeat intervention after 1 year. Although both groups improved in VAS scores from baseline, 73% (37 of 51 patients) in the PRP group versus 49% (24 of 49 patients) in the corticosteroid group were considered to have a successful response at 1 year ($P < .001$). Furthermore, 73% (37 of 51 patients) in the PRP group versus 51% (25 of 49 patients) in the corticosteroid group noted improved Disability of Arm, Shoulder, and Hand scores at 1 year ($P = .005$). Patients who received PRP also continued to report symptom relief 1 year after receiving the injection, whereas the short-term benefits of corticosteroids began to wane after 12 weeks. The improvement within this group of patients who received PRP continued to be noted 2 years after the PRP injection.¹⁷

- Summary and Recommendations: PRP is an effective treatment for lateral epicondylitis, with high-quality evidence demonstrating short-term and long-term efficacy. This recommendation also has been supported by previous reviews^{42,44,45} and best available evidence specifically suggests LR-PRP should be the treatment of choice.

Patellar Tendinopathy

Results from randomized controlled trials (RCTs) appear to support the use of LR-PRP to treat chronic refractory patellar tendinopathy. Dragoo and colleagues²⁵ evaluated

Table 2
Study design characteristics for PRP versus control injection for tendinopathies

Indication	Study and Year of Publication	Level of Evidence	Sample Size		Type of PRP	Number of Injections	Intervention/Injection Volume and Contents		Follow-up, mo	Favors PRP?
			PRP	Control			PRP	Control		
Achilles tendinopathy	Boesen et al, ¹² 2017	I	20	20	LP-PRP	4	4 mL PRP + eccentric training	Sham injection + eccentric training	6	+
Achilles Tendinopathy	de Jonge et al, ¹³ 2011	I	27	27	LR-PRP	1	4 mL PRP	4 mL normal saline	12	–
Achilles tendinopathy	Krogh et al, ¹⁴ 2016	I	12	12	LR-PRP	1	10–15 mL lidocaine → 6 mL PRP	10–15 mL lidocaine → 6 mL normal saline	3	–
Lateral epicondylitis	Behera et al, ¹⁵ 2015	I	15	10	LP-PRP	1	3 mL PRP + .5 mL calcium chloride	3 mL bupivacaine + 0.5 mL normal saline	12	+
Lateral epicondylitis	Gautam et al, ¹⁶ 2015	I	15	15	LP-PRP	1	2 mL PRP	2 mL methylprednisolone	6	+
Lateral epicondylitis	Gosens et al, ¹⁷ 2011	I	51	49	LR-PRP	1	3 mL PRP	3 mL triamcinolone	24	+
Lateral epicondylitis	Krogh et al, ¹⁸ 2013	I	20	20	LR-PRP	1	10–15 mL lidocaine → 3 mL PRP	10–15 mL lidocaine → 1 mL triamcinolone + 2 mL lidocaine	3	–
Lateral epicondylitis	Lebiedzinski et al, ¹⁹ 2015	I	64	56	LP-PRP	1	3 mL PRP	1 mL betamethasone + 2 mL lidocaine	12	+
Lateral epicondylitis	Mishra et al, ²⁰ 2013	II	112	113	LR-PRP	1	Bupivacaine → 2–3 mL PRP	Bupivacaine → 2–3 mL bupivacaine	6	+
Lateral epicondylitis	Montalvan et al, ²¹ 2016	I	25	25	LP-PRP	2	2 mL lidocaine → 2 mL PRP	2 mL lidocaine → 2 mL normal saline	12	–
Lateral epicondylitis	Palacio et al, ²² 2016	I	20	20	LP-PRP	1	3 mL PRP	3 mL dexamethasone	6	–
Lateral epicondylitis	Stenhouse et al, ²³ 2013	I	15	13	LP-PRP	2	1–2 mL lidocaine → 2 mL PRP	1–2 mL lidocaine	6	–

(continued on next page)

Table 2
(continued)

Indication	Study and Year of Publication	Level of Evidence	Sample Size		Type of PRP	Number of Injections	Intervention/Injection Volume and Contents		Follow-up, mo	Favors PRP?
			PRP	Control			PRP	Control		
Lateral epicondylitis	Yadav et al, ²⁴ 2015	I	30	30	LR-PRP	1	1 mL PRP	1 mL methylprednisolone	3	+
Patellar tendinopathy	Dragoo et al, ²⁵ 2014	I	10	13	LR-PRP	1	3 mL bupivacaine → 6 mL PRP + dry needling	3 mL bupivacaine + dry needling	6	+
Patellar tendinopathy	Vetrano et al, ²⁶ 2013	I	23	23	NR	2	2 mL PRP	Extracorporeal shock wave therapy	12	+
Plantar fasciitis	Acosta-Olivo et al, ²⁷ 2016	I	14	14	NR	1	3 mL of PRP + .45 mL of 10% calcium gluconate + lidocaine	2 mL dexamethasone + 2 mL of lidocaine	4	—
Plantar fasciitis	Aksahin et al, ²⁸ 2012	II	30	30	LR-PRP	1	3 mL PRP + 2 mL prilocaine	2 mL methylprednisolone + 2 mL prilocaine	6	—
Plantar fasciitis	Jain et al, ²⁹ 2015	I	30	30	LR-PRP	1	2.5 mL PRP	1 mL triamcinolone + levobupivacaine + sodium bicarbonate	12	—
Plantar fasciitis	Jain et al, ³⁰ 2018	II	40	40	LR-PRP	1	2 mL lidocaine → 3 mL PRP	2 mL methylprednisolone + 2 mL lidocaine	6	—
Plantar fasciitis	Mahindra et al, ³¹ 2016	I	25	25	NR	1	2.5–3 mL PRP	2 mL methylprednisolone	3	+
Plantar fasciitis	Monto, ³² 2014	I	20	20	LR-PRP	1	3 mL PRP + 6 mL bupivacaine	1 mL methylprednisolone + 6 mL bupivacaine	24	+
Plantar fasciitis	Omar et al, ³³ 2012	II	15	15	NR	1	NR PRP	NR corticosteroid	1	+
Plantar fasciitis	Say et al, ³⁴ 2014	II	25	25	NR	1	2.5 mL of PRP + 5.5% calcium chloride	1 mL methylprednisolone + 1 mL of prilocaine	6	+

Plantar fasciitis	Sherpy et al, ³⁵ 2015	I	25	25	LR-PRP	1	PRP + mepivacaine	1 mL triamcinolone + mepivacaine	3	–
Plantar fasciitis	Shetty et al, ³⁶ 2014	II	30	30	LR-PRP	1	8 mL PRP	1 mL triamcinolone + 3 mL lidocaine	3	+
Plantar fasciitis	Tiwari et al, ³⁷ 2013	I	30	30	LR-PRP	1	5 mL PRP	1 mL methylprednisolone + 1 mL prilocaine	6	+
Plantar fasciitis	Vahdatpour et al, ³⁸ 2016	I	16	16	LR-PRP	1	3 mL PRP	1 mL methylprednisolone + 1 mL lidocaine	6	+
Rotator cuff tendinopathy	Kesikburun et al, ³⁹ 2013	I	20	20	LR-PRP	1	1 mL lidocaine → 5 mL PRP	1 mL lidocaine → 5 mL normal saline	12	–
Rotator cuff tendinopathy	Rha et al, ⁴⁰ 2013	I	20	19	LR-PRP	2	<1 mL lidocaine → 3 mL PRP	<1 mL lidocaine	6	+
Rotator cuff tendinopathy	Shams et al, ⁴¹ 2016	I	20	20	LP-PRP	1	2–2.5 mL PRP	5 mL triamcinolone	6	–

Abbreviations: →, denotes sequential injection; LP-PRP, leukocyte-poor PRP; LR-PRP, leukocyte-rich PRP; NR, not reported; PRP, platelet-rich plasma. +, indicates that the trial found in favor of PRP; –, indicates the trial did not favor of PRP.

23 patients with patellar tendinopathy on examination and MRI who had failed conservative management. Patients were randomized to receive ultrasound-guided dry needling alone or with injection of LR-PRP. Patients were followed for more than 26 weeks. At 12 weeks, the PRP group had improved, as measured by Victorian Institute of Sports Assessment, Patellar Tendon (VISA-P) score, significantly more than the dry needling group ($P = .02$). However, the difference was not significant at more than 26 weeks ($P = .66$), suggesting that the benefit of PRP for patellar tendinopathy may be *earlier* improvement of symptoms. Vetrano and colleagues²⁶ also reported the benefit of PRP injections for treatment of chronic refractory patellar tendinopathy. Forty-six patients with ultrasound-confirmed chronic unilateral patellar tendinopathy were randomized to receive either 2 PRP injections over 2 weeks or 3 sessions of focused extracorporeal shock wave therapy (ECSWT). Although there was no significant difference between groups at 2-month follow-up, the PRP group showed statistically significant improvement, as measured by VISA-P and VAS, over ECSWT at 6-month and 12-month follow-up, and as measured by Blazina scale score at 12-month follow-up ($P < .05$ for all).

- **Summary and Recommendations:** A small amount of high-quality evidence supports the use of PRP in chronic refractory patellar tendinopathy and LR-PRP is recommended. Given the small number of studies supporting this conclusion, further clinical trials will help make this suggestion more robust.

Achilles Tendinopathy

In a prospective randomized trial, de Vos and colleagues^{46,47} found no significant benefits with LR-PRP versus a saline solution injection as an adjunct to eccentric exercises for mid-Achilles tendinosis. The investigators reported no significant differences in Achilles tendon structure, the degree of neovascularization, and clinical outcome compared with the saline solution group. In a follow-up study on the same patients, de Jonge and colleagues¹³ similarly reported no significant benefit in terms of pain reduction, activity level, and tendon appearance on ultrasound at 1 year after injection of PRP for chronic Achilles tendinopathy. A more recent RCT by Boesen and colleagues¹² compared 4 LP-PRP injections each 14 days apart against sham injection with a few drops of subcutaneous saline. All participants performed eccentric Achilles training and the group treated with PRP had significantly improved pain, function, and activity scores at all time points throughout the 6-month follow-up period compared with sham injection. Of note, however, this study also found a comparable improvement with a single high-volume injection (50 mL) of 0.5% bupivacaine (10 mL), methylprednisolone (20 mg), and normal saline (40 mL).

- **Summary and Recommendations:** Evidence for the use of PRP in Achilles tendinopathy is mixed at best, and therefore routine use of PRP in Achilles tendinopathy is not supported by current literature. As stated, one clinical trial¹² reported efficacy of 4 LP-PRP injections, but also found similar results for high-volume injection of anesthetic, corticosteroid, and saline, perhaps suggesting the benefit may be due to mechanical volume effects.

Rotator Cuff Tendinopathy

Few high-level RCTs have analyzed PRP as a conservative management strategy for rotator cuff pathology. Kesikburun and colleagues³⁹ looked at subacromial PRP injections in patients with chronic rotator cuff pathology (pain >3 months, with MRI confirming pathology, and >50% relief with subacromial anesthetic injection). The study found no difference in its patient-reported outcome scores when compared with a placebo

subacromial injection of saline. In contrast, in an RCT, Rha and colleagues⁴⁰ demonstrated significant improvements in pain following 2 injections of LR-PRP 4 weeks apart compared with placebo. Shams and colleagues⁴¹ reported comparable improvements between subacromial PRP and corticosteroid injection in Western Ontario Rotator Cuff Index, Shoulder Pain Disability Index, and VAS shoulder pain with Neer test.

- **Summary and Recommendations:** Although there remains a paucity of evidence to routinely recommend PRP injections for rotator cuff tendinopathy, PRP may be a safe and effective alternative to corticosteroid injections in conservative treatment of rotator cuff tendinopathy.

Plantar Fasciitis

Several RCTs have evaluated PRP injection in the management of chronic plantar fasciitis. Although the current standard injection therapy following failure of more conservative management has been a local injection of corticosteroid, it often requires multiple injections that can be associated with fat pad atrophy or plantar fascia rupture.⁴⁸ The potential of PRP as a local injection treatment mitigates these concerns. Two recent meta-analyses^{49,50} evaluated PRP injections against corticosteroid injections, concluding that PRP injections were a viable alternative to corticosteroid injections with respect to efficacy, with some studies demonstrating superiority of PRP.^{31–34,36–38} Given the small sample sizes and limited number of high-quality RCTs, larger-scale high-quality RCTs with more extensive follow-up will be warranted.

- **Summary and Recommendations:** PRP injections are an effective treatment for improving pain and function in chronic plantar fasciitis and may be superior to corticosteroids, especially considering the complications of multiple corticosteroid injections that are not associated with PRP.

OSTEOARTHRITIS

When considering biologic approaches to cartilage pathology, it is important to understand that osteoarthritis (OA) has unique characteristics with respect to joint biology, homeostasis, and levels of metalloproteases and inflammatory cytokines.⁵¹ The idea of using PRP for cartilage regeneration is based on in vitro basic science literature that suggests that growth factors released by the platelet alpha granules may increase the synthetic capacity of chondrocytes through upregulation of gene expression, proteoglycan production, and deposition of type II collagen.^{52–54} Clinical reports on the use of PRP for cartilage injury have involved patients with OA of the knee or hip (**Table 3**).

Osteoarthritis of the Knee

There have been a large volume of studies assessing the efficacy of intra-articular PRP injections for OA of the knee. PRP has been compared against placebo, other alternative injections (corticosteroid, hyaluronic acid [HA]), oral medication (Tylenol 500 mg every 8 hours), homeopathic treatments (ozone therapy), and lifestyle changes.⁷⁴ Shen and colleagues⁷⁵ performed a meta-analysis looking at 14 RCTs comprising 1423 patients. Individual RCTs had different preparations of PRP including LR-PRP, LP-PRP, and plasma rich in growth factor (PRGF) Endoret.⁷⁵ The meta-analysis demonstrated that multiple injections of PRP showed significant improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores at 3-month, 6-month, and 12-month follow-ups when compared with the controls ($P = .02, .004, < .001$, respectively), and PRP did not show increased risk of

Table 3
Study design characteristics for PRP versus control injection for osteoarthritis

Indication	Study and Year of Publication	Level of Evidence	Sample Size		Type of PRP	Number of Injections	Intervention/Injection Volume and Contents		Follow-up, mo	Favors PRP?
			PRP	Control			PRP	Control		
Hip OA	Battaglia et al, ⁵⁵ 2013	I	50	50	LR-PRP	3	5 mL PRP	30 mg HA	12	–
Hip OA	Dallari et al, ⁵⁶ 2016	I	44, +HA:31	36	NR	3	7 mL PRP + HA	30 mg HA	12	+
Hip OA	Doria et al, ⁵⁷ 2017	II	40	40	NR	3	5 mL PRP	15 mg HA	12	–
Hip OA	Sante et al, ⁵⁸ 2016	I	21	22	NR	3	3 mL PRP	30 mg HA	4	+
Knee OA	Cerza et al, ⁵⁹ 2012	I	60	60	LP-PRP	4	5.5 mL PRP	20 mg HA	4	+
Knee OA	Cole et al, ⁶⁰ 2017	I	49	50	LP-PRP	3	4 mL PRP	16 mg HA injection	12	+
Knee OA	Duyms et al, ⁶¹ 2017	I	41	HA:40, Ozone:39	NR	2	5 mL PRP	40 mg HA, 15 mL ozone	12	+
Knee OA	Filardo et al, ⁶² 2015	I	96	96	LR-PRP	3	5 mL PRP	30 mg HA	12	–
Knee OA	Filardo et al, ⁶³ 2012	I	54	55	LR-PRP	3	5 mL PRP	NR HA	12	–
Knee OA	Gormeli et al, ⁶⁴ 2017	I	PRP(3x):46 PRP(1x):45	HA:46, Placebo:45	NR	3 vs 1	5 mL PRP	30 mg HA, NR saline	6	+
Knee OA	Lana et al, ⁶⁵ 2016	I	36, +HA: 33	36	NR	3	5 mL PRP + 20 mg HA	20 mg HA	12	+
Knee OA	Montanez et al, ⁶⁶ 2016	I	28	27	NR	3	NR	NR HA	6	+

Knee OA	Patel et al, ⁶⁷ 2013	I	PRP1:27 PRP2:25	Placebo:26	LP-PRP	1 vs 2	8 mL PRP	8 mL Saline	6	+
Knee OA	Paterson et al, ⁶⁸ 2016	I	12	11	NR	3	3 mL PRP	3 mL HA	3	—
Knee OA	Raeissadat et al, ⁶⁹ 2015	I	87	73	LR-PRP	2	4–6 mL PRP	20 mg HA	12	+
Knee OA	Rayegani et al, ⁷⁰ 2014	I	31	31	LR-PRP	2	4–6 mL PRP + therapeutic exercise	Therapeutic exercise alone	6	+
Knee OA	Sanchez et al, ⁷¹ 2012	I	89	87	LP-PRP	3	8 mL PRGF	NR HA	6	+
Knee OA	Simental et al, ⁷² 2016	I	33	32	LP-PRP	3	3 mL PRP	Tylenol 500 mg q8h	4	+
Knee OA	Smith et al, ⁷³ 2016	I	15	15	LP-PRP	3	3–8 mL PRP	3–8 mL Saline	12	+
Knee OA	Vaquerizao et al, ⁷⁴ 2013	I	48	48	LP-PRP	3	8 mL PRGF	NR HA	11	+

Abbreviations: HA, hyaluronic acid; LP-PRP, leukocyte-poor PRP; LR-PRP, leukocyte-rich PRP; NR, not reported; OA, osteoarthritis; PRGF, plasma rich in growth factors.

postinjection adverse effects (Relative risk 1.40; 95% confidence interval 0.80–2/40; $I^2 = 59\%$; $P = .24$).⁷⁵ They concluded that intra-articular PRP injections are more efficacious in the treatment of knee OA with respect to pain relief and patient-reported outcomes versus other alternative injections.

In the various individual studies within that meta-analysis, it was shown that many subjects who underwent intra-articular injections of PRP reported pain relief compared with baseline. On subgroup analysis examining the efficacy of PRP-based severity of knee OA, PRP was shown more effective in patients with mild to moderate OA.^{59,61,64–66,68,69,71} However, a few studies demonstrated no difference in WOMAC scores when compared with HA injection,^{60,62,63,67} whereas other studies showed diminishing results in pain relief and function after a certain amount of time.⁶⁸ One possible explanation for this discrepancy is the heterogeneity of the PRP preparations and regimens being evaluated for OA of the knee.

A meta-analysis by Riboh and colleagues⁷⁶ compared LP-PRP and LR-PRP in the treatment of knee osteoarthritis and found that LP-PRP injections resulted in significantly improved WOMAC scores compared with HA^{59,71} or placebo.^{67,77} Patel and colleagues⁶⁷ performed a prospective randomized trial comparing single-injection or double-injection LP-PRP with saline solution in 78 patients with early OA. They concluded that a single injection of PRP was as effective as a double injection. On the other hand, Filardo and colleagues⁶² enrolled 192 patients in a randomized controlled study and found no difference between LR-PRP and HA, providing further evidence that LP-PRP may be an effective choice for treatment of OA symptoms, whereas LR-PRP appears not to be.⁷⁶ The biological basis for this may be in the relative level of inflammatory versus anti-inflammatory mediators present in LR-PRP and LP-PRP. Inflammatory mediators TNF- α , IL-6, interferon- γ , and IL-1 β are increased significantly in the presence of LR-PRP,^{10,78,79} whereas injection of LP-PRP increases IL-4 and IL-10, which are anti-inflammatory mediators. IL-10 specifically was found to be helpful in the treatment of hip OA,⁵⁶ and may also suppress the release of the inflammatory mediators TNF- α , IL-6, and IL-1 β , and block the inflammatory pathway by neutralizing nuclear factor- κ B activity.^{10,56,70,72,78} In addition to its deleterious effects on chondrocytes, LR-PRP may also fail to help treat OA symptoms due to its effect on synoviocytes. Braun and colleagues⁸⁰ found that treatment of synovial cells with LR-PRP or erythrocytes resulted in significant proinflammatory mediator production and cell death.

- Summary and Recommendations: Intra-articular injection of LP-PRP is a safe treatment option for knee OA, and many RCTs have demonstrated its ability to reduce pain symptoms and increase.^{73,75} Larger studies with longer follow-up need to be done to characterize its long-term efficacy.

Osteoarthritis of the Hip

Compared with knee OA, studies on the effects of PRP for hip OA have been limited, with 4 RCTs (to date) comparing PRP injections for OA of the hip with HA injections. Battaglia and colleagues⁵⁵ compared clinical efficacy of PRP and HA injections in 100 patients with chronic symptomatic hip OA. Patients were randomized to the 2 groups, and VAS and Harris Hip Score (HHS) outcomes were measured at baseline and at 1, 3, 6, and 12 months. Both PRP and HA injections demonstrated significant improvement at all time points with peak improvement at 3 months, and gradual diminishing effects thereafter to 12 months. The outcome scores at 12 months still displayed significant improvement when compared with baseline ($P < .0005$)⁵⁵; however, there was no statistically significant difference between PRP and HA treatment groups.

Di Sante and colleagues⁵⁸ looked at 43 patients with severe hip OA who were randomized to receive either an intra-articular PRP injection or an intra-articular HA injection. Outcomes were measured using the VAS and WOMAC pain scores at baseline, 4 weeks, and 16 weeks following treatment. In the PRP group, VAS scores significantly decreased at 4 weeks but not at 16, suggesting an initial, but not sustained reduction in pain. Interestingly, the HA group saw a significant difference at week 16, but not week 4 when compared with baseline.⁵⁸

Dallari and colleagues⁵⁶ evaluated PRP against HA injections for hip OA, and also compared the combination of HA and PRP injected together to both injections alone. The PRP group was found to have the lowest VAS score of all 3 groups at all follow-up periods (2 months, 6 months, and 12 month). The PRP group also had a significantly better WOMAC score at 2 and 6 months, but not at 12 months. In a different study, Doria and colleagues⁵⁷ performed a double-blind RCT comparing patients who received 3 consecutive weekly injections of PRP versus 3 HA injections. The study showed no significant difference between the PRP and HA groups, but both groups showed improved HHS, WOMAC, and VAS scores at 6 and 12 months following treatment. None of the studies showed an adverse effect from intra-articular PRP injections into the hip and all concluded that PRP was safe.

Overall, although limited data, intra-articular injection of PRP for hip OA has been shown to be safe and have some efficacy in pain reduction and function as measured by patient-reported outcome scores. Multiple studies have shown PRP to initially have a better pain reduction when compared with HA; however, that initial advantage seems to decrease over time with PRP and HA having very similar efficacy by 12 months.

- Summary and Recommendations: PRP may have some efficacy for early and temporal pain relief in hip OA and overall had very similar efficacy as HA injections. As there have been a small number of clinical studies evaluating the use of PRP for OA of the hip, more level I evidence is needed to determine if PRP can be used as an alternative conservative treatment to delay surgery for OA of the hip.

SURGICAL AUGMENTATION

Rotator Cuff Repair

Several high-level clinical studies have evaluated the use of PRP products as augmentations in arthroscopic repair of rotator cuff tears (**Table 4**). Many of the studies have specifically analyzed the use of platelet-rich fibrin matrix preparation for augmentation (PRFM),^{81,82,90,91,93} whereas other studies analyzed the use of injected PRP directly into the repair site.^{87,89,94} There is, however, significant heterogeneity of the PRP or PRFM preparations in these studies. Results were obtained with patient-directed outcomes, most commonly University of California–Los Angeles (UCLA), American Shoulder and Elbow Society (ASES) and Constant Shoulder scores, Simple Shoulder Test (SST) scores, and VAS pain scores. Some studies have also used imaging, such as ultrasound and MRI, to measure differences in tendon healing, healing time, and retear rates. Objective clinical data, such as rotator cuff strength and shoulder range of motion (ROM) have also been collected to measure functional outcome differences.^{39,84,86,87,91} Most of the data have shown little utility for PRP in rotator cuff tendinopathy or as augmentation in arthroscopic rotator cuff repair.^{39,82,83,86,88–91,93,95,96} However, limited data have shown some effect in reducing perioperative pain.^{41,86,89,95}

Saltzman and colleagues⁹⁷ and Filardo and colleagues⁹⁸ performed large meta-analyses, and showed that PRP had no significant benefit in augmentation of

Table 4
Study design characteristics of surgical augmentation with PRP in rotator cuff repair

Indication	Study and Year of Publication	Level of Evidence	Sample Size		Type of PRP	Number of Injections	Intervention/Injection Volume and Contents		Follow-up, mo	Favors PRP?
			PRP	Control			PRP	Control		
Rotator cuff repair	Bergeson et al, ⁸¹ 2012	III	16	21	PRFM	1	PRFM + single-row or double-row repair	Single-row or double-row repair	12	–
Rotator cuff repair	Castricini et al, ⁸² 2011	I	43	45	NR-PRFM	1	PRFM + double-row repair	Double-row repair	16	–
Rotator cuff repair	D'Ambrosi et al, ⁸³ 2016	I	20	20	NR	1	16 mL PRP + single-row repair	Single-row repair	6	+
Rotator cuff repair	Ebert et al, ⁸⁴ 2017	I	30	30	LP-PRP	2 (day 7 and 14)	2–4 mL PRP + double-row repair	Double-row repair	42	+
Rotator cuff repair	Gumina et al, ⁸⁵ 2012	I	39	37	LR-PRFM	1	PRFM + single-row repair	Single-row repair	12	–
Rotator cuff repair	Holtby et al, ⁸⁶ 2016	I	41	41	LP-PRP	1	7 mL PRP + single-row repair	Single-row repair	6	–
Rotator cuff repair	Jo et al, ⁸⁷ 2015	I	37	37	LP-PRP	3	3 mL PRP gel + double-row repair	Double-row repair	12	+
Rotator cuff repair	Malavolta et al, ⁸⁸ 2014	I	27	27	LR-PRP	1	20 mL PRP + single-row repair	Single-row repair	24	–
Rotator cuff repair	Randelli et al, ⁸⁹ 2011	I	26	27	LR-PRP	1	6 mL PRP + single-row repair	Single-row repair	24	+
Rotator cuff repair	Rodeo et al, ⁹⁰ 2012	II	40	39	PRFM	1	PRFM + single-row or double-row repair	Single-row or double-row repair	12	–
Rotator cuff repair	Weber et al, ⁹¹ 2013	I	30	30	LP-PRFM	1	PRFM clot + single-row repair	Single-row repair	12	–
Rotator cuff repair	Zumstein et al, ⁹² 2016	I	17	18	LR-PRFM	1	PRFM + double-row repair	Double-row repair	12	–

Abbreviations: LP-PRP, leukocyte-poor PRP; LR-PRP, leukocyte-rich PRP; NR, not reported; PRFM, platelet-rich fibrin matrix. +, indicates that the trial found in favor of PRP; –, indicates the trial did not favor of PRP.

arthroscopically repaired rotator cuffs. Saltzman and colleagues⁹⁷ looked at 7 meta-analyses encompassing a total of 3193 patients. At mean follow-up of 12 to 21 months, no significant difference was found when compared with controls in 5 of 6 studies measuring constant scores, 6 of 6 measuring UCLA scores, 4 of 5 measuring ASES scores, and 3 of 5 measuring SST scores. However, a subgroup analysis did see a trend toward better outcomes with PRP in the form of PRFM; in the treatment of small and medium tears versus large/massive tears; when applied to the tendon-bone interface versus over the tendon; and when applied with double-row versus single-row rotator cuff repairs.⁹⁷

Vavken and colleagues⁹⁹ performed a meta-analysis of 14 studies looking at PRP-augmented rotator cuff repairs. They were divided into subgroups of small and medium tears (<3 cm) and large tears (>3 cm). In large tears, there were no beneficial effects of PRP-augmented surgery. In small and medium tears, there was a beneficial effect of reducing retear rates ($P = .038$).

Some individual studies have determined a utility for PRP in different tear sizes and patterns. Cai and colleagues⁹⁶ found PRP augmentation to be associated with a lower failure to heal rate in small to moderate tears. Jo and colleagues⁸⁷ found that PRP application with medium and large tear repairs led to a decrease in retear rates (3% vs 20% in the conventional group) and an increased cross-sectional area of the supraspinatus on follow-up MRI when compared with no augmentation. Potentially due to the anti-inflammatory properties of PRP, PRP application has been shown to reduce pain in the early postoperative period following surgery.^{83,86,89} Flury and colleagues⁹⁵ showed similar pain reduction when compared with an injection of ropivacaine.

- **Summary and Recommendations:** Evidence from randomized clinical trials and large meta-analyses do not demonstrate an absolute benefit of PRP augmentation in rotator cuff repair surgery. A recent critical analysis review¹⁰⁰ reached a similar conclusion that PRP could not be routinely recommended as an augmentation in rotator cuff repair, but that activated PRFM delivered at the bone-tendon interface in conjunction with double-row repair technique had the best results in subgroup analyses. Some limited data have shown PRP may be useful in reducing postoperative pain and repair of small and medium tears.

Achilles Tendon Repair

The effects of PRP to augment healing in Achilles tendon ruptures have been promising in preclinical models. Most studies in rodents show a beneficial effect of platelets on the healing of acute Achilles tendon ruptures when used as an adjunctive therapy.^{101–108} Caution is warranted, however, when extrapolating results from preclinical Achilles rupture models to human patients,¹⁰⁹ due to the difference in the size of the tendons between species, which has significant effects in terms of diffusion and cellular migration distances.¹¹⁰ Furthermore, rodents tend to load their healing Achilles tendons to a greater extent than humans, which leads to more favorable biomechanical outcomes.¹¹¹

Clinical trials in humans are limited with respect to the use of PRP in the repair of acute Achilles tendon tears, and their findings are somewhat conflicting. Schepull and colleagues¹¹² evaluated the use of PRP in Achilles tendon repair in a randomized study ($n = 30$) in which PRP was injected into the injury site at the time of primary suture repair. Although no differences were reported with regard to tendon elasticity and heel raise index between the PRP and control groups, the investigators did note a lower Achilles Tendon Total Rupture score among the PRP group, which suggests a detrimental effect of PRP on subjective outcome after repair. Additionally, another study

also demonstrated equivalence in structural and functional results in patients with Achilles tendon ruptures surgically treated with and without addition of PRP.¹¹³ However, Zou and colleagues¹¹⁴ enrolled 36 patients with acute Achilles tendon rupture in a prospective randomized controlled study using intraoperative LR-PRP injection versus repair without PRP. Patients were followed for 24 months. Patients from the PRP group had better isokinetic muscle at 3 months and had higher SF-36 and Leppilahti scores at 6 and 12 months, respectively ($P < .05$ for all). Ankle ROM was also significantly better in the PRP group at all time points of 6, 12, and 24 months ($P < .001$).

- Summary and Recommendations: Injection of PRP is not definitively beneficial as a surgical augmentation for acute Achilles tendon repair, although the available literature is conflicting.

Anterior Cruciate Ligament Surgery

The success of anterior cruciate ligament (ACL) surgery not only hinges on technical factors (eg, graft-tunnel placement and graft fixation) but also biologic healing of the ACL graft. Studies on the use of PRP in ACL reconstruction surgery have focused on 3 biologic processes: (1) osteoligamentous integration of the graft into the tibial and femoral tunnels, (2) maturation of the articular portion of the graft, (3) and graft harvest site healing and pain reduction.¹¹⁵ Within the literature, ACL graft maturation tends to be assessed with MRI. The assumption is that a low homogeneous intensity signal on T2-weighted and proton density-weighted MRI is likely indicative of a healthy maturing ACL graft. In terms of the effect of PRP on ACL graft maturation, some studies have demonstrated improved graft maturation with PRP,^{116–119} whereas others report no significant differences.^{120,121} The investigators of a recent systematic review of 11 controlled trials, which included studies in which statistical significance was not reached, concluded that PRP likely improves ACL graft maturation by up to 50%. The investigators pointed to insufficient sample size as a potential rationale for lack of statistical significance despite MRI improvement in some metrics measuring ACL graft maturation.¹²²

The other component to successful biologic healing of an ACL graft is graft–bone tunnel incorporation. Recent data on the use of PRP to augment healing of the graft–bone interface has shown no clinical benefit of PRP in tunnel widening or osteointegration of the graft.^{120,123} Vogrin and colleagues¹²¹ evaluated the effects of PRP gel treatment for hamstring autograft ACL reconstruction in a controlled, double-blind study. The investigators reported MRI evidence of improved vascularization along the ACL graft–bone interface at 3 months with use of PRP, but the observed benefit dissipated by 6 months after surgery. Other studies have similarly reported limited to no evidence to support the use of PRP to augment ACL graft–bone tunnel incorporation.^{116,124} Of note is that nearly all of the studies used an LR-PRP formulation, and LR-PRP formulations increase local tissue inflammation, which may delay or alter healing.⁸

One final point of consideration is whether any of the observed benefit of PRP on ACL graft maturation or graft-tunnel healing would translate into improved clinical results. The best available evidence seems to suggest no significant benefit for functional outcomes with PRP augmentation.^{116,120,125} Ventura and colleagues¹²⁵ found no differences in knee injury and osteoarthritis outcome score (KOOS) scores, Tegner scores, or KT-1000 measurements between the PRP-treated group and control subjects at 6 months after surgery, despite reporting a significant difference in graft appearance. Orrego and colleagues¹¹⁶ similarly noted no significant benefit in both Lysholm and International Knee Documentation Committee (IKDC) scores at 6 months after surgery, despite identifying a positive effect of PRP on graft maturation. Current

literature suggests that PRP may improve the rate at which ACL grafts achieve a low signal on MRI T2-weighted imaging, but likely has little to no effect on graft-tunnel incorporation. A demonstrable benefit in patient outcome after use of PRP in patients undergoing ACL surgery is also lacking.

Other clinical trials have assessed the impact of PRP on donor site (graft harvest site) pain and healing, with some promising early results. De Almeida and colleagues¹²⁶ looked at adding PRP to the patellar tendon harvest site and measuring patient-reported pain scores and patellar tendon gapping on MRI at 6 months following surgery. The investigators found that patients reported better immediate postoperative pain scores, and at 6 months there was significantly less gapping on MRI, although isokinetic testing results were no different.¹²⁶ Seijas and colleagues¹²⁷ looked at anterior knee pain after bone-patellar-bone autograft ACL reconstruction with PRP application, and found decreased anterior knee pain when compared with controls. In a different study, Cervellin and colleagues¹²⁸ did not see a significant difference in VAS pain scores, but found that the PRP group had a significantly higher VISA score.

- **Summary and Recommendations:** More studies are needed to investigate the effect of PRP on ACL graft integration, maturation, and donor site pain. Early studies have shown no significant clinical effect of PRP on graft integration or maturation, but newer studies have shown promising results in decreasing donor site pain.

ANKLE SPRAINS

There are very little high-level data analyzing PRP injections in ankle sprains, with (to date) 2 published RCTs available. Rowden and colleagues¹²⁹ performed a double-blinded placebo-controlled randomized clinical trial of patients with acute ankle sprains in the emergency room comparing ultrasound-guided LR-PRP injections with local anesthetic versus injection of normal saline with local anesthetic. Injections were performed adjacent to an injured ligament if visualized on ultrasound or otherwise were injected into the site of maximal tenderness. For all patients, a posterior splint was placed with non-weight-bearing restrictions for 3 days. Pain medication was given at the physician's discretion. Primary outcome measures were VAS pain score and Lower Extremity Functional Scale (LEFS) on day 0 (baseline), day 3, and day 8. The investigators found that there was no statistical difference in the VAS pain score or LEFS between the 2 groups.¹ Laver and colleagues¹³⁰ randomized 16 elite athletes diagnosed with high ankle sprains, including an injured anteroinferior tibiofibular ligament to treatment with either an ultrasound-guided LP-PRP injection at initial presentation with a repeat injection 7 days later in conjunction with a rehabilitation program, versus rehabilitation program alone. Primary outcomes were measured by return-to-play and dynamic imaging studies. All patients received the same rehabilitation protocol and return-to-play criteria. The study found the LP-PRP group returned to play in a shorter amount of time (40.8 days) compared with the control (59.6 days, $P < .006$).¹³⁰ Only 1 patient had residual pain after return to play in the PRP group, whereas 5 patients had residual pain in the control. No significant difference was seen in the dynamic imaging studies in external rotation between the 2 groups 6 weeks post injury.

- **Summary and Recommendations:** PRP has not been shown to be efficacious in the setting of acute ankle sprains, but limited evidence suggests that LP-PRP injections may be helpful in high ankle sprains to reduce return-to-play time and decrease incidence of residual pain in elite athletes. However, due to the limited amount of high-level evidence, the use of PRP injections cannot be routinely recommended for high ankle sprains.

MUSCLE INJURIES

The use of PRP in the treatment of muscle injuries has attracted a significant amount of interest in recent years. Similar to tendon healing, the steps in muscle healing involve the initial inflammatory response, which is followed by cell proliferation, differentiation, and tissue remodeling. Hamid and colleagues¹³¹ conducted a single-blind randomized study of 28 patients with grade 2 hamstring muscle injuries comparing an injection of LR-PRP with a rehabilitation program, versus rehabilitation alone. The group treated with LR-PRP was able to return to play in a significantly shorter amount of time compared with controls (average 26.7 vs 42.5 days, $P = .02$), but structural improvement was not achieved. In a double-blind RCT, Reurink and colleagues¹³² evaluated 80 patients comparing intramuscular PRP injections for the treatment of acute hamstring muscle injuries as diagnosed on MRI with placebo saline injections, with all patients receiving standard rehabilitation. The patients were followed for 6 months, and the investigators reported no significant differences between the groups in return-to-play time or in reinjury rates.

Although clinical studies have not found PRP to be efficacious in treating muscle injuries, basic science research may lead to an improved understanding of treatment modalities. In vitro work has found that PRP is capable of leading to myoblast proliferation, but not to myoblast differentiation,¹³³ a requisite step in producing muscle tissue. Furthermore, growth factors contained in platelets, specifically myostatin and TGF- β 1, are actually detrimental to muscle regeneration.^{134,135} Miroshnychenko and colleagues¹³⁶ found in vitro that treatment with PPP or PRP with a second spin to remove the platelets induced myoblasts into muscle differentiation. This suggests that perhaps the most beneficial treatment of muscle injuries may be with PPP, although in vivo animal studies followed by human clinical trials will be necessary to further explore this treatment option in the future.

- Summary and Recommendations: PRP injections have not been found to be an efficacious treatment modality in the treatment of muscle injuries in current clinical studies, but preclinical studies suggest that perhaps future clinical investigation into the use of PPP or PRP with platelets removed may be beneficial.

FRACTURE AND NONUNION MANAGEMENT

Most preclinical investigations favor the use of PRP to improve bone healing.^{137,138} This is mainly due to accelerated and increased bone regeneration demonstrated in fracture models treated with PRP.^{139–146} Additionally, PRP treatment has been shown to ameliorate bone strength in a rodent osteotomy model.¹⁴⁴ In isolation, however, PRP treatment alone does not effectively heal critical-sized bone defects.^{147–149}

Despite the positive findings in the preclinical literature, there is no consensus to support the routine use of PRP to enhance bone healing based on high-quality clinical studies. To this point, a recent review of PRP and acute fracture treatment notes that 3 of the included RCTs failed to show benefit with respect to functional outcomes, whereas 2 of the included studies showed superior clinical outcomes.¹³⁸ Most trials in this review (6 of 8) studied efficacy of PRP when combined with other biologics, such as mesenchymal stem cells and/or bone graft, to promote fracture healing. In terms of nonunion treatment, there was only 1 RCT identified reporting clinical outcomes measures. This study failed to show a benefit of PRP when compared with bone morphogenetic protein 7 (which is standard of care) when treating tibia nonunions.¹⁵⁰

- Summary and Recommendations: Current evidence does not support the use of PRP in acute fracture or nonunion management

SUMMARY OF RECOMMENDATIONS

PRP remains a promising treatment for musculoskeletal maladies, and clinical data to date have shown that PRP is safe. However, evidence of its efficacy has been mixed and highly variable depending on the specific indication. Additional future high-quality large clinical trials will be critical in shaping our perspective of this treatment option. The heterogeneity of PRP preparations, both presently and historically, leads sweeping recommendations about its utility impossible to make. This heterogeneity has also made interpreting existing literature more complicated. Nonetheless, based on the current best available literature, the following recommendations are summarized:

- There is abundant high-quality level I evidence to recommend LR-PRP injections for lateral epicondylitis and LP-PRP injections for OA of the knee
- There is a moderate amount of high-quality level I evidence to recommend LR-PRP injections for patellar tendinopathy and PRP injections for plantar fasciitis
- There is currently insufficient high-quality evidence for recommendation, but small clinical trials have shown promising efficacy for PRP injections for rotator cuff tendinopathy, OA of the hip, donor site pain in ACL reconstruction with patellar tendon autograft, and LP-PRP injections for high ankle sprains
- The best available clinical evidence does not demonstrate efficacy of PRP injections for Achilles tendinopathy, acute fracture, or nonunion; surgical augmentation with PRP in rotator cuff repair, Achilles tendon repair, and ACL reconstruction; and efficacy has not been shown with PRP injections for muscle injuries, although preclinical studies suggest PRP may hold promise for muscle injuries but clinical trials will be necessary to validate this.

REFERENCES

1. Boswell SG, Cole BJ, Sundman EA, et al. Platelet-rich plasma: a milieu of bioactive factors. *Arthroscopy* 2012;28(3):429–39.
2. Foster TE, Puskas BL, Mandelbaum BR, et al. Platelet-rich plasma: from basic science to clinical applications. *Am J Sports Med* 2009;37(11):2259–72.
3. Le A, Dragoo JL. Orthobiologics: clinical application of platelet-rich plasma and stem cell therapy. In: DeLee & Drez's orthopaedic sports medicine. 5th edition. Elsevier; in press.
4. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? *Implant Dent* 2001;10(4):225–8.
5. Degen RM, Bernard JA, Oliver KS, et al. Commercial separation systems designed for preparation of platelet-rich plasma yield differences in cellular composition. *HSS J* 2017;13(1):75–80.
6. Magalon J, Bausset O, Serratrice N, et al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. *Arthroscopy* 2014;30(5):629–38.
7. Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. *Am J Sports Med* 2011;39(2):266–71.
8. Dragoo JL, Braun HJ, Durham JL, et al. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. *Am J Sports Med* 2012;40(6):1274–81.
9. Mazzocca AD, McCarthy MBR, Chowaniec DM, et al. Platelet-rich plasma differs according to preparation method and human variability. *J Bone Joint Surg Am* 2012;94(4):308–16.

10. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. *Am J Sports Med* 2011;39(10):2135–40.
11. McCarrel T, Fortier L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. *J Orthop Res* 2009;27(8):1033–42.
12. Boesen AP, Hansen R, Boesen MI, et al. Effect of high-volume injection, platelet-rich plasma, and sham treatment in chronic midportion Achilles tendinopathy: a randomized double-blinded prospective study. *Am J Sports Med* 2017;45(9):2034–43.
13. de Jonge S, de Vos RJ, Weir A, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. *Am J Sports Med* 2011;39(8):1623–9.
14. Krogh TP, Ellingsen T, Christensen R, et al. Ultrasound-guided injection therapy of Achilles tendinopathy with platelet-rich plasma or saline: a randomized, blinded, placebo-controlled trial. *Am J Sports Med* 2016;44(8):1990–7.
15. Behera P, Dhillon M, Aggarwal S, et al. Leukocyte-poor platelet-rich plasma versus bupivacaine for recalcitrant lateral epicondylar tendinopathy. *J Orthop Surg* 2015;23(1):6–10.
16. Gautam V, Verma S, Batra S, et al. Platelet-rich plasma versus corticosteroid injection for recalcitrant lateral epicondylitis: clinical and ultrasonographic evaluation. *J Orthop Surg* 2015;23(1):1–5.
17. Gosens T, Peerbooms JC, van Laar W, et al. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. *Am J Sports Med* 2011;39(6):1200–8.
18. Krogh TP, Fredberg U, Stengaard-Pedersen K, et al. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. *Am J Sports Med* 2013;41(3):625–35.
19. Lebiecziński R, Synder M, Buchcic P, et al. A randomized study of autologous conditioned plasma and steroid injections in the treatment of lateral epicondylitis. *Int Orthop* 2015;39(11):2199–203.
20. Mishra AK, Skrepnik NV, Edwards SG, et al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. *Am J Sports Med* 2014;42(2):463–71.
21. Montalvan B, Le Goux P, Klouche S, et al. Inefficacy of ultrasound-guided local injections of autologous conditioned plasma for recent epicondylitis: results of a double-blind placebo-controlled randomized clinical trial with one-year follow-up. *Rheumatology* 2016;55(2):279–85.
22. Palacio EP, Schiavetti RR, Kanematsu M, et al. Effects of platelet-rich plasma on lateral epicondylitis of the elbow: prospective randomized controlled trial. *Rev Bras Ortop* 2016;51(1):90–5.
23. Stenhouse G, Sookur P, Watson M. Do blood growth factors offer additional benefit in refractory lateral epicondylitis? A prospective, randomized pilot trial of dry needling as a stand-alone procedure versus dry needling and autologous conditioned plasma. *Skeletal Radiol* 2013;42(11):1515–20.
24. Yadav R. Comparison of local injection of platelet rich plasma and corticosteroids in the treatment of lateral epicondylitis of humerus. *J Clin Diagn Res* 2015;9(7):RC05–7.

25. Dragoo JL, Wasterlain AS, Braun HJ, et al. Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind, randomized controlled trial. *Am J Sports Med* 2014;42(3):610–8.
26. Vetrano M, Castorina A, Vulpiani MC, et al. Platelet-rich plasma versus focused shock waves in the treatment of jumper's knee in athletes. *Am J Sports Med* 2013;41(4):795–803.
27. Acosta-Olivo C, Elizondo-Rodriguez J, Lopez-Cavazos R, et al. Plantar fasciitis—a comparison of treatment with intralesional steroids versus platelet-rich plasma randomized, blinded study. *J Am Podiatr Med Assoc* 2017;107(6):490–6.
28. Akşahin E, Doğruyol D, Yüksel HY, et al. The comparison of the effect of corticosteroids and platelet-rich plasma (PRP) for the treatment of plantar fasciitis. *Arch Orthop Trauma Surg* 2012;132(6):781–5.
29. Jain K, Murphy PN, Clough TM. Platelet rich plasma versus corticosteroid injection for plantar fasciitis: a comparative study. *Foot* 2015;25(4):235–7.
30. Jain SK, Suprashant K, Kumar S, et al. Comparison of plantar fasciitis injected with platelet-rich plasma vs corticosteroids. *Foot Ankle Int* 2018;39(7):780–6.
31. Mahindra P, Yamin M, Selhi HS, et al. Chronic plantar fasciitis: effect of platelet-rich plasma, corticosteroid, and placebo. *Orthopedics* 2016;39(2):e285–9.
32. Monto RR. Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis. *Foot Ankle Int* 2014;35(4):313–8.
33. Omar AS, Ibrahim ME, Ahmed AS, et al. Local injection of autologous platelet rich plasma and corticosteroid in treatment of lateral epicondylitis and plantar fasciitis: randomized clinical trial. *Egypt Rheumatol* 2012;34(2):43–9.
34. Say F, Gürler D, İnkaya E, et al. Comparison of platelet-rich plasma and steroid injection in the treatment of plantar fasciitis. *Acta Orthop Traumatol Turc* 2014;48(6):667–72.
35. Sherpy NA, Hammad MA, Hagrass HA, et al. Local injection of autologous platelet rich plasma compared to corticosteroid treatment of chronic plantar fasciitis patients: a clinical and ultrasonographic follow-up study. *Egypt Rheumatol* 2016;38(3):247–52.
36. Shetty VD, Dhillion M, Hegde C, et al. A study to compare the efficacy of corticosteroid therapy with platelet-rich plasma therapy in recalcitrant plantar fasciitis: a preliminary report. *Foot Ankle Surg* 2014;20(1):10–3.
37. Tiwari M, Bhargava R. Platelet rich plasma therapy: a comparative effective therapy with promising results in plantar fasciitis. *J Clin Orthop Trauma* 2013;4(1):31–5.
38. Vahdatpour B, Kianimehr L, Moradi A, et al. Beneficial effects of platelet-rich plasma on improvement of pain severity and physical disability in patients with plantar fasciitis: a randomized trial. *Adv Biomed Res* 2016;5:179.
39. Kesikburun S, Tan AK, Yılmaz B, et al. Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up. *Am J Sports Med* 2013;41(11):2609–16.
40. Rha D, Park G-Y, Kim Y-K, et al. Comparison of the therapeutic effects of ultrasound-guided platelet-rich plasma injection and dry needling in rotator cuff disease: a randomized controlled trial. *Clin Rehabil* 2013;27(2):113–22.
41. Shams A, El-Sayed M, Gamal O, et al. Subacromial injection of autologous platelet-rich plasma versus corticosteroid for the treatment of symptomatic partial rotator cuff tears. *Eur J Orthop Surg Traumatol* 2016;26(8):837–42.
42. Miller LE, Parrish WR, Roides B, et al. Efficacy of platelet-rich plasma injections for symptomatic tendinopathy: systematic review and meta-analysis of

- randomised injection-controlled trials. *BMJ Open Sport Exerc Med* 2017;3(1): e000237.
43. Peerbooms JC, Sluimer J, Bruijn DJ, et al. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. *Am J Sports Med* 2010;38(2):255–62.
 44. Arirachakaran A, Sukthuyat A, Sisayanarane T, et al. Platelet-rich plasma versus autologous blood versus steroid injection in lateral epicondylitis: systematic review and network meta-analysis. *J Orthop Traumatol* 2016;17(2):101–12.
 45. Krogh TP, Bartels EM, Ellingsen T, et al. Comparative effectiveness of injection therapies in lateral epicondylitis: a systematic review and network meta-analysis of randomized controlled trials. *Am J Sports Med* 2013;41(6):1435–46.
 46. de Vos RJ, Weir A, van Schie HTM, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. *JAMA* 2010;303(2):144–9.
 47. de Vos RJ, Weir A, Tol JL, et al. No effects of PRP on ultrasonographic tendon structure and neovascularisation in chronic midportion Achilles tendinopathy. *Br J Sports Med* 2011;45(5):387–92.
 48. Neufeld SK, Cerrato R. Plantar fasciitis: evaluation and treatment. *J Am Acad Orthop Surg* 2008;16(6):338–46.
 49. Yang W-Y, Han Y-H, Cao X-W, et al. Platelet-rich plasma as a treatment for plantar fasciitis: a meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2017;96(44):e8475.
 50. Singh P, Madanipour S, Bhamra JS, et al. A systematic review and meta-analysis of platelet-rich plasma versus corticosteroid injections for plantar fasciopathy. *Int Orthop* 2017;41(6):1169–81.
 51. Pearle AD, Warren RF, Rodeo SA. Basic science of articular cartilage and osteoarthritis. *Clin Sports Med* 2005;24(1):1–12.
 52. Spreafico A, Chellini F, Frediani B, et al. Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes. *J Cell Biochem* 2009;108(5):1153–65.
 53. Sun Y, Feng Y, Zhang CQ, et al. The regenerative effect of platelet-rich plasma on healing in large osteochondral defects. *Int Orthop* 2010;34(4):589–97.
 54. Smyth NA, Murawski CD, Fortier LA, et al. Platelet-rich plasma in the pathologic processes of cartilage: review of basic science evidence. *Arthroscopy* 2013;29(8):1399–409.
 55. Battaglia M, Guaraldi F, Vannini F, et al. Efficacy of ultrasound-guided intra-articular injections of platelet-rich plasma versus hyaluronic acid for hip osteoarthritis. *Orthopedics* 2013;36(12):e1501–8.
 56. Dallari D, Stagni C, Rani N, et al. Ultrasound-guided injection of platelet-rich plasma and hyaluronic acid, separately and in combination, for hip osteoarthritis: a randomized controlled study. *Am J Sports Med* 2016;44(3):664–71.
 57. Doria C, Mosele GR, Caggiari G, et al. Treatment of early hip osteoarthritis: ultrasound-guided platelet rich plasma versus hyaluronic acid injections in a randomized clinical trial. *Joints* 2017;5(3):152–5.
 58. Sante LD, Villani C, Santilli V, et al. Intra-articular hyaluronic acid vs platelet-rich plasma in the treatment of hip osteoarthritis. *Med Ultrason* 2016;18(4):463–8.
 59. Cerza F, Carni S, Carcangiu A, et al. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. *Am J Sports Med* 2012;40(12):2822–7.

60. Cole BJ, Karas V, Hussey K, et al. Hyaluronic acid versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on intra-articular biology for the treatment of knee osteoarthritis. *Am J Sports Med* 2017;45(2):339–46.
61. Duymus TM, Mutlu S, Dernek B, et al. Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options. *Knee Surg Sports Traumatol Arthrosc* 2017;25(2):485–92.
62. Filardo G, Di Matteo B, Di Martino A, et al. Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: a randomized controlled trial. *Am J Sports Med* 2015;43(7):1575–82.
63. Filardo G, Kon E, Di Martino A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. *BMC Musculoskelet Disord* 2012;13:229.
64. Görmeli G, Görmeli CA, Ataoglu B, et al. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: a randomized, double-blind, placebo-controlled trial. *Knee Surg Sports Traumatol Arthrosc* 2017;25(3):958–65.
65. Lana JFSD, Weglein A, Sampson SE, et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. *J Stem Cells Regen Med* 2016;12(2):69–78.
66. Montañez-Heredia E, Irizar S, Huertas PJ, et al. Intra-articular injections of platelet-rich plasma versus hyaluronic acid in the treatment of osteoarthritic knee pain: a randomized clinical trial in the context of the Spanish National Health Care System. *Int J Mol Sci* 2016;17(7) [pii:E1064].
67. Patel S, Dhillon MS, Aggarwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. *Am J Sports Med* 2013;41(2):356–64.
68. Paterson KL, Nicholls M, Bennell KL, et al. Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: a double-blind, randomized controlled pilot study. *BMC Musculoskelet Disord* 2016; 17:67.
69. Raeissadat SA, Rayegani SM, Hassanabadi H, et al. Knee osteoarthritis injection choices: Platelet-Rich Plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). *Clin Med Insights Arthritis Musculoskelet Disord* 2015;8: 1–8.
70. Rayegani SM, Raeissadat SA, Taheri MS, et al. Does intra articular platelet rich plasma injection improve function, pain and quality of life in patients with osteoarthritis of the knee? A randomized clinical trial. *Orthop Rev* 2014;6(3):5405.
71. Sánchez M, Fiz N, Azofra J, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. *Arthroscopy* 2012;28(8):1070–8.
72. Simental-Mendía M, Vílchez-Cavazos JF, Peña-Martínez VM, et al. Leukocyte-poor platelet-rich plasma is more effective than the conventional therapy with acetaminophen for the treatment of early knee osteoarthritis. *Arch Orthop Trauma Surg* 2016;136(12):1723–32.
73. Smith PA. Intra-articular autologous conditioned plasma injections provide safe and efficacious treatment for knee osteoarthritis: an FDA-sanctioned, randomized, double-blind, placebo-controlled clinical trial. *Am J Sports Med* 2016; 44(4):884–91.

74. Vaquerizo V, Plasencia MÁ, Arribas I, et al. Comparison of intra-articular injections of Plasma Rich in Growth Factors (PRGF-Endoret) versus durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial. *Arthroscopy* 2013;29(10):1635–43.
75. Shen L, Yuan T, Chen S, et al. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. *J Orthop Surg* 2017;12(1):16.
76. Riboh JC, Saltzman BM, Yanke AB, et al. Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. *Am J Sports Med* 2016;44(3):792–800.
77. Hart R, Safi A, Komzák M, et al. Platelet-rich plasma in patients with tibiofemoral cartilage degeneration. *Arch Orthop Trauma Surg* 2013;133(9):1295–301.
78. Civinini R, Nistri L, Martini C, et al. Growth factors in the treatment of early osteoarthritis. *Clin Cases Miner Bone Metab* 2013;10(1):26–9.
79. Carballo CB, Nakagawa Y, Sekiya I, et al. Basic science of articular cartilage. *Clin Sports Med* 2017;36(3):413–25.
80. Braun HJ, Kim HJ, Chu CR, et al. The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy. *Am J Sports Med* 2014;42(5):1204–10.
81. Bergeson AG, Tashjian RZ, Greis PE, et al. Effects of platelet-rich fibrin matrix on repair integrity of at-risk rotator cuff tears. *Am J Sports Med* 2012;40(2):286–93.
82. Castricini R, Longo UG, De Benedetto M, et al. Platelet-rich plasma augmentation for arthroscopic rotator cuff repair: a randomized controlled trial. *Am J Sports Med* 2011;39(2):258–65.
83. D'Ambrosi R, Palumbo F, Paronzi A, et al. Platelet-rich plasma supplementation in arthroscopic repair of full-thickness rotator cuff tears: a randomized clinical trial. *Musculoskelet Surg* 2016;100(S1):25–32.
84. Ebert JR, Wang A, Smith A, et al. A midterm evaluation of postoperative platelet-rich plasma injections on arthroscopic supraspinatus repair: a randomized controlled trial. *Am J Sports Med* 2017;45(13):2965–74.
85. Gumina S, Campagna V, Ferrazza G, et al. Use of platelet-leukocyte membrane in arthroscopic repair of large rotator cuff tears: a prospective randomized study. *J Bone Joint Surg Am* 2012;94(15):1345–52.
86. Holtby R, Christakis M, Maman E, et al. Impact of platelet-rich plasma on arthroscopic repair of small- to medium-sized rotator cuff tears: a randomized controlled trial. *Orthop J Sports Med* 2016;4(9). 232596711666559.
87. Jo CH, Shin JS, Shin WH, et al. Platelet-rich plasma for arthroscopic repair of medium to large rotator cuff tears: a randomized controlled trial. *Am J Sports Med* 2015;43(9):2102–10.
88. Malavolta EA, Gracitelli MEC, Ferreira Neto AA, et al. Platelet-rich plasma in rotator cuff repair: a prospective randomized study. *Am J Sports Med* 2014;42(10):2446–54.
89. Randelli P, Arrigoni P, Ragone V, et al. Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up. *J Shoulder Elbow Surg* 2011;20(4):518–28.
90. Rodeo SA, Delos D, Williams RJ, et al. The effect of platelet-rich fibrin matrix on rotator cuff tendon healing: a prospective, randomized clinical study. *Am J Sports Med* 2012;40(6):1234–41.
91. Weber SC, Kauffman JI, Parise C, et al. Platelet-rich fibrin matrix in the management of arthroscopic repair of the rotator cuff: a prospective, randomized, double-blinded study. *Am J Sports Med* 2013;41(2):263–70.

92. Zumstein MA, Rumian A, Thélu CÉ, et al. SECEC Research Grant 2008 II: Use of platelet- and leucocyte-rich fibrin (L-PRF) does not affect late rotator cuff tendon healing: a prospective randomized controlled study. *J Shoulder Elbow Surg* 2016;25(1):2–11.
93. Barber FA. Triple-loaded single-row versus suture-bridge double-row rotator cuff tendon repair with platelet-rich plasma fibrin membrane: a randomized controlled trial. *Arthroscopy* 2016;32(5):753–61.
94. Pandey V, Bandi A, Madi S, et al. Does application of moderately concentrated platelet-rich plasma improve clinical and structural outcome after arthroscopic repair of medium-sized to large rotator cuff tear? A randomized controlled trial. *J Shoulder Elbow Surg* 2016;25(8):1312–22.
95. Flury M, Rickenbacher D, Schwyzer H-K, et al. Does pure platelet-rich plasma affect postoperative clinical outcomes after arthroscopic rotator cuff repair? A randomized controlled trial. *Am J Sports Med* 2016;44(8):2136–46.
96. Cai Y, Zhang C, Lin X. Efficacy of platelet-rich plasma in arthroscopic repair of full-thickness rotator cuff tears: a meta-analysis. *J Shoulder Elbow Surg* 2015;24(12):1852–9.
97. Saltzman BM, Jain A, Campbell KA, et al. Does the use of platelet-rich plasma at the time of surgery improve clinical outcomes in arthroscopic rotator cuff repair when compared with control cohorts? A systematic review of meta-analyses. *Arthroscopy* 2016;32(5):906–18.
98. Filardo G, Di Matteo B, Kon E, et al. Platelet-rich plasma in tendon-related disorders: results and indications. *Knee Surg Sports Traumatol Arthrosc* 2018;26(7):1984–99.
99. Vavken P, Sadoghi P, Palmer M, et al. Platelet-rich plasma reduces retear rates after arthroscopic repair of small- and medium-sized rotator cuff tears but is not cost-effective. *Am J Sports Med* 2015;43(12):3071–6.
100. Smith KM, Le A, Costouros J, et al. Biologics for rotator cuff repair: a critical analysis review. *JBJS Rev*, in press.
101. Allahverdi A, Sharifi D, Takhtfooladi MA, et al. Evaluation of low-level laser therapy, platelet-rich plasma, and their combination on the healing of Achilles tendon in rabbits. *Lasers Med Sci* 2015;30(4):1305–13.
102. Chen L, Dong SW, Liu JP, et al. Synergy of tendon stem cells and platelet-rich plasma in tendon healing. *J Orthop Res* 2012;30(6):991–7.
103. Kaux JF, Drion PV, Colige A, et al. Effects of platelet-rich plasma (PRP) on the healing of Achilles tendons of rats. *Wound Repair Regen* 2012;20(5):748–56.
104. Kim HJ, Nam HW, Hur CY, et al. The effect of platelet rich plasma from bone marrow aspirate with added bone morphogenetic protein-2 on the Achilles tendon-bone junction in rabbits. *Clin Orthop Surg* 2011;3(4):325–31.
105. Lyras DN, Kazakos K, Georgiadis G, et al. Does a single application of PRP alter the expression of IGF-I in the early phase of tendon healing? *J Foot Ankle Surg* 2011;50(3):276–82.
106. Lyras DN, Kazakos K, Tryfonidis M, et al. Temporal and spatial expression of TGF-beta1 in an Achilles tendon section model after application of platelet-rich plasma. *Foot Ankle Surg* 2010;16(3):137–41.
107. Yuksel S, Gulec MA, Gultekin MZ, et al. Comparison of the early period effects of bone marrow-derived mesenchymal stem cells and platelet-rich plasma on the Achilles tendon ruptures in rats. *Connect Tissue Res* 2016;57(5):360–73.
108. Sadoghi P, Rosso C, Valderrabano V, et al. The role of platelets in the treatment of Achilles tendon injuries. *J Orthop Res* 2013;31(1):111–8.

109. Aspenberg P. Platelet concentrates and Achilles tendon healing. *J Orthop Res* 2013;31(9):1500.
110. Andersson T, Eliasson P, Hammerman M, et al. Low-level mechanical stimulation is sufficient to improve tendon healing in rats. *J Appl Physiol* 1985 2012;113(9):1398–402.
111. Virchenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks? Interplay between early regeneration and mechanical stimulation. *Acta Orthop* 2006;77(5):806–12.
112. Schepull T, Kvist J, Norrman H, et al. Autologous platelets have no effect on the healing of human Achilles tendon ruptures: a randomized single-blind study. *Am J Sports Med* 2011;39(1):38–47.
113. De Carli A, Lanzetti RM, Ciompi A, et al. Can platelet-rich plasma have a role in Achilles tendon surgical repair? *Knee Surg Sports Traumatol Arthrosc* 2016;24(7):2231–7.
114. Zou J, Mo X, Shi Z, et al. A prospective study of platelet-rich plasma as biological augmentation for acute Achilles tendon rupture repair. *Biomed Res Int* 2016;2016:1–8.
115. Di Matteo B, Loibl M, Andriolo L, et al. Biologic agents for anterior cruciate ligament healing: a systematic review. *World J Orthop* 2016;7(9):592–603.
116. Orrego M, Larrain C, Rosales J, et al. Effects of platelet concentrate and a bone plug on the healing of hamstring tendons in a bone tunnel. *Arthroscopy* 2008;24(12):1373–80.
117. Radice F, Yáñez R, Gutiérrez V, et al. Comparison of magnetic resonance imaging findings in anterior cruciate ligament grafts with and without autologous platelet-derived growth factors. *Arthroscopy* 2010;26(1):50–7.
118. Seijas R, Ares O, Catala J, et al. Magnetic resonance imaging evaluation of patellar tendon graft remodelling after anterior cruciate ligament reconstruction with or without platelet-rich plasma. *J Orthop Surg (Hong Kong)* 2013;21(1):10–4.
119. Sánchez M, Anitua E, Azofra J, et al. Ligamentization of tendon grafts treated with an endogenous preparation rich in growth factors: gross morphology and histology. *Arthroscopy* 2010;26(4):470–80.
120. Nin JRV, Gasque GM, Azcárate AV, et al. Has platelet-rich plasma any role in anterior cruciate ligament allograft healing? *Arthroscopy* 2009;25(11):1206–13.
121. Vogrin M, Ruprecht M, Dinevski D, et al. Effects of a platelet gel on early graft revascularization after anterior cruciate ligament reconstruction: a prospective, randomized, double-blind, clinical trial. *Eur Surg Res* 2010;45(2):77–85.
122. Andriolo L, Di Matteo B, Kon E, et al. PRP augmentation for ACL reconstruction. *Biomed Res Int* 2015;2015:1–15.
123. Mirzatolooie F, Alamdari MT, Khalkhali HR. The impact of platelet-rich plasma on the prevention of tunnel widening in anterior cruciate ligament reconstruction using quadrupled autologous hamstring tendon. *Bone Joint J* 2013;95-B(1):65–9.
124. Figueroa D, Melean P, Calvo R, et al. Magnetic resonance imaging evaluation of the integration and maturation of semitendinosus-gracilis graft in anterior cruciate ligament reconstruction using autologous platelet concentrate. *Arthroscopy* 2010;26(10):1318–25.
125. Ventura A, Terzaghi C, Borgo E, et al. Use of growth factors in ACL surgery: preliminary study. *J Orthop Traumatol* 2005;6(2):76–9.
126. de Almeida AM, Demange MK, Sobrado MF, et al. Patellar tendon healing with platelet-rich plasma: a prospective randomized controlled trial. *Am J Sports Med* 2012;40(6):1282–8.

127. Seijas R, Cuscó X, Sallent A, et al. Pain in donor site after BTB-ACL reconstruction with PRGF: a randomized trial. *Arch Orthop Trauma Surg* 2016;136(6): 829–35.
128. Cervellin M, de Girolamo L, Bait C, et al. Autologous platelet-rich plasma gel to reduce donor-site morbidity after patellar tendon graft harvesting for anterior cruciate ligament reconstruction: a randomized, controlled clinical study. *Knee Surg Sports Traumatol Arthrosc* 2012;20(1):114–20.
129. Rowden A, Dominici P, D’Orazio J, et al. Double-blind, randomized, placebo-controlled study evaluating the use of Platelet-rich Plasma Therapy (PRP) for acute ankle sprains in the emergency department. *J Emerg Med* 2015;49(4): 546–51.
130. Laver L, Carmont MR, McConkey MO, et al. Plasma rich in growth factors (PRGF) as a treatment for high ankle sprain in elite athletes: a randomized control trial. *Knee Surg Sports Traumatol Arthrosc* 2015;23(11):3383–92.
131. A Hamid MS, Mohamed Ali MR, Yusof A, et al. Platelet-rich plasma injections for the treatment of hamstring injuries: a randomized controlled trial. *Am J Sports Med* 2014;42(10):2410–8.
132. Reurink G, Goudswaard GJ, Moen MH, et al. Platelet-rich plasma injections in acute muscle injury. *N Engl J Med* 2014;370(26):2546–7.
133. Li H, Usas A, Poddar M, et al. Platelet-rich plasma promotes the proliferation of human muscle derived progenitor cells and maintains their stemness. *PLoS One* 2013;8(6):e64923.
134. Artaza JN, Bhasin S, Magee TR, et al. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. *Endocrinology* 2005;146(8):3547–57.
135. Burks TN, Cohn RD. Role of TGF- β signaling in inherited and acquired myopathies. *Skelet Muscle* 2011;1(1):19.
136. Miroshnychenko O, Chang W, Dragoo JL. The use of platelet-rich and platelet-poor plasma to enhance differentiation of skeletal myoblasts: implications for the use of autologous blood products for muscle regeneration. *Am J Sports Med* 2017;45(4):945–53.
137. Marcuzzan S, Taschieri S, Weinstein RL, et al. Efficacy of platelet concentrates in bone healing: a systematic review on animal studies—Part B: large-size animal models. *Platelets* 2018;29(4):338–46.
138. Roffi A, Di Matteo B, Krishnakumar GS, et al. Platelet-rich plasma for the treatment of bone defects: from pre-clinical rational to evidence in the clinical practice. A systematic review. *Int Orthop* 2017;41(2):221–37.
139. Cho K, Kim JM, Kim MH, et al. Scintigraphic evaluation of osseointegrative response around calcium phosphate-coated titanium implants in tibia bone: effect of platelet-rich plasma on bone healing in dogs. *Eur Surg Res* 2013;51(3–4): 138–45.
140. Archundia TR, Soriano JC, Corona JN. Utility of platelet-rich plasma and growth factors bone in the bone defects. Regional Hospital Lic. Adolfo Lopez Mateos, ISSSTE. *Acta Ortop Mex* 2007;21(5):256–60 [in Spanish].
141. Batista MA, Leivas TP, Rodrigues CJ, et al. Comparison between the effects of platelet-rich plasma and bone marrow concentrate on defect consolidation in the rabbit tibia. *Clinics (Sao Paulo)* 2011;66(10):1787–92.
142. Dulgeroglu TC, Metineren H. Evaluation of the effect of platelet-rich fibrin on long bone healing: an experimental rat model. *Orthopedics* 2017;40(3):e479–84.

143. Gianakos A, Zambrana L, Savage-Elliott I, et al. Platelet-rich plasma in the animal long-bone model: an analysis of basic science evidence. *Orthopedics* 2015;38(12):e1079–90.
144. Guzel Y, Karalezli N, Bilge O, et al. The biomechanical and histological effects of platelet-rich plasma on fracture healing. *Knee Surg Sports Traumatol Arthrosc* 2015;23(5):1378–83.
145. Simman R, Hoffmann A, Bohinc RJ, et al. Role of platelet-rich plasma in acceleration of bone fracture healing. *Ann Plast Surg* 2008;61(3):337–44.
146. Zhang N, Wu YP, Qian SJ, et al. Research progress in the mechanism of effect of PRP in bone deficiency healing. *ScientificWorldJournal* 2013;2013:134582.
147. Cheng X, Lei D, Mao T, et al. Repair of critical bone defects with injectable platelet rich plasma/bone marrow-derived stromal cells composite: experimental study in rabbits. *Ulus Travma Acil Cerrahi Derg* 2008;14(2):87–95.
148. Kanthan SR, Kavitha G, Addi S, et al. Platelet-rich plasma (PRP) enhances bone healing in non-united critical-sized defects: a preliminary study involving rabbit models. *Injury* 2011;42(8):782–9.
149. Sarkar MR, Augat P, Shefelbine SJ, et al. Bone formation in a long bone defect model using a platelet-rich plasma-loaded collagen scaffold. *Biomaterials* 2006;27(9):1817–23.
150. Calori GM, Tagliabue L, Gala L, et al. Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomised clinical study on 120 patients. *Injury* 2008;39(12):1391–402.